Nuclear medicine advances in breast cancer imaging

E. Bombardieri, F. Crippa, S. M. Baio, B. A M Peeters, M. Greco, E. K J Pauwels

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Primary breast cancer imaging can be done by various means. Mammography is the most widely used technique because of its excellent diagnostic performance, patient compliance, and cost-effectiveness ratio. Other radiological techniques (such as ultrasonography) are indicated in particular circumstances, while some (such as digital mammography and magnetic resonance imaging) seem very promising but are still under evaluation. The recent technological progress in nuclear medicine has resulted in the availability of two diagnostic procedures that have been validated by extensive international clinical experience: Scintimammography with Sesta-MIBI and positron emission tomography (PET) with fluorodeoxyglucose (FDG). The general advantage of nuclear medicine imaging is that tumor-seeking radiopharmaceuticals accumulate in cancer lesions, which makes scintimammography and PET fundamentally different from the radiological techniques that image the tumor mainly on the basis of morphological alterations. Scintimammography is indicated for the study of breast lesions in patients in whom mammography is non-diagnostic or difficult to interpret; it may be useful also to assess and even predict the response to primary chemotherapy. FDG-PET is increasingly used in oncology and is particularly useful in breast cancer as it gives more accurate information than scintimammography in the evaluation of patients with ambiguous mammographies and in discriminating between viable tumor, fibrotic scar or necrosis following surgery, chemo- or radiotherapy. The FDG uptake in the tumor correlates with the histological grade and potential aggressiveness of breast cancer, which may have prognostic implications. In addition to its usefulness in the study of breast lesions, FDG-PET shows great efficacy in detecting lymph node involvement prior to surgery. Whole-body PET provides information on soft tissue and bone metastases in a single scanning session, and has an important clinical role in detecting recurrent metastatic disease. On the basis of the above-mentioned evidence, nuclear medicine techniques, integrated with radiological techniques, offer an interesting opportunity to improve the diagnostic imaging yield in breast cancer, which will eventually lead to better patient management. This paper reports on the latest developments in this field.

Original languageEnglish
Pages (from-to)277-287
Number of pages11
JournalTumori
Volume87
Issue number5
Publication statusPublished - 2001

Fingerprint

Nuclear Medicine
Positron-Emission Tomography
Mammography
Breast Neoplasms
Neoplasms
Breast
Drug Therapy
Radiopharmaceuticals
Diagnostic Imaging
Patient Compliance
Cost-Benefit Analysis
Cicatrix
Ultrasonography
Necrosis
Radiotherapy
Lymph Nodes
Magnetic Resonance Imaging
Neoplasm Metastasis
Bone and Bones

Keywords

  • Breast cancer
  • FDG-PET
  • Scintimammography
  • Sesta-MIBI

ASJC Scopus subject areas

  • Cancer Research

Cite this

Bombardieri, E., Crippa, F., Baio, S. M., Peeters, B. A. M., Greco, M., & Pauwels, E. K. J. (2001). Nuclear medicine advances in breast cancer imaging. Tumori, 87(5), 277-287.

Nuclear medicine advances in breast cancer imaging. / Bombardieri, E.; Crippa, F.; Baio, S. M.; Peeters, B. A M; Greco, M.; Pauwels, E. K J.

In: Tumori, Vol. 87, No. 5, 2001, p. 277-287.

Research output: Contribution to journalArticle

Bombardieri, E, Crippa, F, Baio, SM, Peeters, BAM, Greco, M & Pauwels, EKJ 2001, 'Nuclear medicine advances in breast cancer imaging', Tumori, vol. 87, no. 5, pp. 277-287.
Bombardieri E, Crippa F, Baio SM, Peeters BAM, Greco M, Pauwels EKJ. Nuclear medicine advances in breast cancer imaging. Tumori. 2001;87(5):277-287.
Bombardieri, E. ; Crippa, F. ; Baio, S. M. ; Peeters, B. A M ; Greco, M. ; Pauwels, E. K J. / Nuclear medicine advances in breast cancer imaging. In: Tumori. 2001 ; Vol. 87, No. 5. pp. 277-287.
@article{eeb72bda46cb4a27921e750d4d757014,
title = "Nuclear medicine advances in breast cancer imaging",
abstract = "Primary breast cancer imaging can be done by various means. Mammography is the most widely used technique because of its excellent diagnostic performance, patient compliance, and cost-effectiveness ratio. Other radiological techniques (such as ultrasonography) are indicated in particular circumstances, while some (such as digital mammography and magnetic resonance imaging) seem very promising but are still under evaluation. The recent technological progress in nuclear medicine has resulted in the availability of two diagnostic procedures that have been validated by extensive international clinical experience: Scintimammography with Sesta-MIBI and positron emission tomography (PET) with fluorodeoxyglucose (FDG). The general advantage of nuclear medicine imaging is that tumor-seeking radiopharmaceuticals accumulate in cancer lesions, which makes scintimammography and PET fundamentally different from the radiological techniques that image the tumor mainly on the basis of morphological alterations. Scintimammography is indicated for the study of breast lesions in patients in whom mammography is non-diagnostic or difficult to interpret; it may be useful also to assess and even predict the response to primary chemotherapy. FDG-PET is increasingly used in oncology and is particularly useful in breast cancer as it gives more accurate information than scintimammography in the evaluation of patients with ambiguous mammographies and in discriminating between viable tumor, fibrotic scar or necrosis following surgery, chemo- or radiotherapy. The FDG uptake in the tumor correlates with the histological grade and potential aggressiveness of breast cancer, which may have prognostic implications. In addition to its usefulness in the study of breast lesions, FDG-PET shows great efficacy in detecting lymph node involvement prior to surgery. Whole-body PET provides information on soft tissue and bone metastases in a single scanning session, and has an important clinical role in detecting recurrent metastatic disease. On the basis of the above-mentioned evidence, nuclear medicine techniques, integrated with radiological techniques, offer an interesting opportunity to improve the diagnostic imaging yield in breast cancer, which will eventually lead to better patient management. This paper reports on the latest developments in this field.",
keywords = "Breast cancer, FDG-PET, Scintimammography, Sesta-MIBI",
author = "E. Bombardieri and F. Crippa and Baio, {S. M.} and Peeters, {B. A M} and M. Greco and Pauwels, {E. K J}",
year = "2001",
language = "English",
volume = "87",
pages = "277--287",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Nuclear medicine advances in breast cancer imaging

AU - Bombardieri, E.

AU - Crippa, F.

AU - Baio, S. M.

AU - Peeters, B. A M

AU - Greco, M.

AU - Pauwels, E. K J

PY - 2001

Y1 - 2001

N2 - Primary breast cancer imaging can be done by various means. Mammography is the most widely used technique because of its excellent diagnostic performance, patient compliance, and cost-effectiveness ratio. Other radiological techniques (such as ultrasonography) are indicated in particular circumstances, while some (such as digital mammography and magnetic resonance imaging) seem very promising but are still under evaluation. The recent technological progress in nuclear medicine has resulted in the availability of two diagnostic procedures that have been validated by extensive international clinical experience: Scintimammography with Sesta-MIBI and positron emission tomography (PET) with fluorodeoxyglucose (FDG). The general advantage of nuclear medicine imaging is that tumor-seeking radiopharmaceuticals accumulate in cancer lesions, which makes scintimammography and PET fundamentally different from the radiological techniques that image the tumor mainly on the basis of morphological alterations. Scintimammography is indicated for the study of breast lesions in patients in whom mammography is non-diagnostic or difficult to interpret; it may be useful also to assess and even predict the response to primary chemotherapy. FDG-PET is increasingly used in oncology and is particularly useful in breast cancer as it gives more accurate information than scintimammography in the evaluation of patients with ambiguous mammographies and in discriminating between viable tumor, fibrotic scar or necrosis following surgery, chemo- or radiotherapy. The FDG uptake in the tumor correlates with the histological grade and potential aggressiveness of breast cancer, which may have prognostic implications. In addition to its usefulness in the study of breast lesions, FDG-PET shows great efficacy in detecting lymph node involvement prior to surgery. Whole-body PET provides information on soft tissue and bone metastases in a single scanning session, and has an important clinical role in detecting recurrent metastatic disease. On the basis of the above-mentioned evidence, nuclear medicine techniques, integrated with radiological techniques, offer an interesting opportunity to improve the diagnostic imaging yield in breast cancer, which will eventually lead to better patient management. This paper reports on the latest developments in this field.

AB - Primary breast cancer imaging can be done by various means. Mammography is the most widely used technique because of its excellent diagnostic performance, patient compliance, and cost-effectiveness ratio. Other radiological techniques (such as ultrasonography) are indicated in particular circumstances, while some (such as digital mammography and magnetic resonance imaging) seem very promising but are still under evaluation. The recent technological progress in nuclear medicine has resulted in the availability of two diagnostic procedures that have been validated by extensive international clinical experience: Scintimammography with Sesta-MIBI and positron emission tomography (PET) with fluorodeoxyglucose (FDG). The general advantage of nuclear medicine imaging is that tumor-seeking radiopharmaceuticals accumulate in cancer lesions, which makes scintimammography and PET fundamentally different from the radiological techniques that image the tumor mainly on the basis of morphological alterations. Scintimammography is indicated for the study of breast lesions in patients in whom mammography is non-diagnostic or difficult to interpret; it may be useful also to assess and even predict the response to primary chemotherapy. FDG-PET is increasingly used in oncology and is particularly useful in breast cancer as it gives more accurate information than scintimammography in the evaluation of patients with ambiguous mammographies and in discriminating between viable tumor, fibrotic scar or necrosis following surgery, chemo- or radiotherapy. The FDG uptake in the tumor correlates with the histological grade and potential aggressiveness of breast cancer, which may have prognostic implications. In addition to its usefulness in the study of breast lesions, FDG-PET shows great efficacy in detecting lymph node involvement prior to surgery. Whole-body PET provides information on soft tissue and bone metastases in a single scanning session, and has an important clinical role in detecting recurrent metastatic disease. On the basis of the above-mentioned evidence, nuclear medicine techniques, integrated with radiological techniques, offer an interesting opportunity to improve the diagnostic imaging yield in breast cancer, which will eventually lead to better patient management. This paper reports on the latest developments in this field.

KW - Breast cancer

KW - FDG-PET

KW - Scintimammography

KW - Sesta-MIBI

UR - http://www.scopus.com/inward/record.url?scp=0035204236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035204236&partnerID=8YFLogxK

M3 - Article

VL - 87

SP - 277

EP - 287

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5

ER -